Abstract: The instant disclosure provides antibodies that specifically bind to CTLA-4 (e.g., human CTLA-4) and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Abstract: The instant disclosure provides antibodies that specifically bind to TIM 3 and antagonize TIM-3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Abstract: A robotic system is configured to autonomously or semi-autonomously rack a circuit breaker from an electrical cabinet or other electrical-connection station. The robotic system may perform work on circuit breakers, ground-and-test devices, or other electrical equipment.

Abstract: The instant disclosure provides antibodies that specifically bind to TIM-3 (e.g., human TIM-3) and antagonize TIM-3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Abstract: The instant disclosure provides antibodies that specifically bind to T-cell immunoreceptor with Ig and ITIM domains (TIGIT) (e.g., human TIGIT) and antagonize TIGIT function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Abstract: Antibodies that specifically bind to TIM 3 and antagonize TIM-3 function pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Abstract: A method of deliquification of production wells includes placing an artificial lift tool in a gas wellbore, where the artificial lift tool includes a rack and multiple piezoelectric transducers. The rack includes multiple trays. Each piezoelectric transducer of the multiple piezoelectric transducers is positioned on a respective tray of the multiple trays. The method further includes providing, by a pump, a liquid on surfaces of the multiple piezoelectric transducers and providing, by a signal source, an electrical signal to the multiple piezoelectric transducers. The method also includes generating, by the multiple piezoelectric transducers, acoustic waves from the electrical signal, where at least some of the liquid provided to the multiple piezoelectric transducers is atomized by the acoustic waves.

Abstract: A phytosanitary treatment blockchain is generated from automatically gathered phytosanitary treatment records. The phytosanitary treatment records are generated by matching authenticated treatment data with authenticated identification data. Matching may be based on geolocation, timestamps, or both. Authentication may be based on digital signatures using private key encryption. Separate treatment sensors and identification sensors automatically gather information about a phytosanitary treatment and the item being treated. The gathered information is encrypted and transmitted to blockchain members that perform authentication, matching, and generation of the phytosanitary treatment blockchain. A tracking code may be issued for each treatment. The tracking code is used to obtain an authentication of the treatment that indicates whether the treatment passed or failed.

Abstract: The instant disclosure provides antibodies that specifically bind to CTLA-4 (e.g., human CTLA-4) and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Abstract: An airport runway arrangement for commercial aircraft comprises a first runway section, a second runway section extending substantially in prolongation of the first runway section and an intermediate section between the first and second runway sections.

Abstract: Provided are novel antigenic polypeptides comprising tumor-associated peptides, and compositions comprising the same. Such antigenic polypeptides and compositions are particularly useful as immunotherapeutics (e.g., cancer vaccines). Also provided are methods of inducing a cellular immune response using the polypeptides and compositions, methods of treating a disease using the polypeptides and compositions, kits comprising the polypeptides and compositions, methods of making the compositions, and antibodies and T cell receptors that specifically bind to the polypeptides.

Abstract: The instant disclosure provides antibodies that specifically bind to CD137 (e.g., human CD137) and increases CD137 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Abstract: A phytosanitary treatment blockchain is generated from automatically gathered phytosanitary treatment records. The phytosanitary treatment records are generated by matching authenticated treatment data with authenticated identification data. Matching may be based on geolocation, timestamps, or both. Authentication may be based on digital signatures using private key encryption. Separate treatment sensors and identification sensors automatically gather information about a phytosanitary treatment and the item being treated. The gathered information is encrypted and transmitted to blockchain members that perform authentication, matching, and generation of the phytosanitary treatment blockchain. A tracking code may be issued for each treatment. The tracking code is used to obtain an authentication of the treatment that indicates whether the treatment passed or failed.

Abstract: A system for servicing cable includes a field-end assembly and a live-end assembly, each mounted on a support structure having at least one drive mechanism operable to cause relative linear movement between the field-end assembly and the live-end assembly. A drilling-and-shorting assembly can create a short circuit in a field-end of the cable, and a continuity tester can test the integrity of the short-circuit. The field end of the cable can then be ejected from the system, and an end-cap-cradle assembly can position an end cap on a live end of an electrical cable and test its installation.

Abstract: A runway arrangement comprising: a first runway section (202-1) designated as a landing runway section; a second runway section (202-2) designated as a take-off runway section; and a sterile safety area (210); wherein the first and second runway sections are linked by the sterile safety area (210); the runway arrangement comprising a missed approach point for aircraft due to land on the first runway section, displaced from the start of the second runway section (202-2) by a distance greater than H/tan ?1; where H is a safe turning height and ?1 is an angle of ascent following a missed approach; wherein H is greater than 150 m and ?1 is greater than 2°.

Abstract: The instant disclosure provides antibodies that specifically bind to CD137 (e.g., human CD137) and increases CD137 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Abstract: The instant disclosure provides antibodies that specifically bind to T-cell immunoreceptor with Ig and ITIM domains (TIGIT) (e.g., human TIGIT) and antagonize TIGIT function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Abstract: A smokeable material for inclusion in a smoking article, the material comprising particles or fragments comprising acacia gum, wherein the particles or fragments do not comprise a diluent, flavourant or aerosol generating material; and substantially comprise or consist of acacia gum.

Abstract: The instant disclosure provides antibodies that specifically bind to CD137 (e.g., human CD137) and increases CD137 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Abstract: A switchable grating for phase contrast imaging comprising a reservoir with a medium and x-ray absorbing particles acoustically connected to a first ultrasound generator and a second ultrasound generator arranged along a side of the reservoir orthogonal to the first side. The ultrasound generators are each, individually or together, configured to generate a soundwave with a frequency and phase such that a standing wave is formed within the medium causing the x-ray absorbing particles to organize along pressure nodes of the standing waves.